FDA Brief

Warning letters Biologics

FDA warning letter to

Louisville Reproductive Center

High riskIssued Jan 23Posted Feb 10Center for Biologics Evaluation and Research

Louisville Reproductive Center failed to properly test and screen semen donors for infectious diseases, FDA found.

What happened

FDA inspected the facility from April 23 to April 28, 2025, and found significant violations of the human cell and tissue rules (21 CFR Part 1271). Directed semen donors were not tested for HIV-1, hepatitis C virus, hepatitis B virus by nucleic acid test, hepatitis B core antibody, West Nile virus, or HTLV-I/II before being deemed eligible, and the donor questionnaire and procedures were missing required risk questions and steps. FDA also said the firm had been cited for similar violations in 2021 and its May 1, 2025 response was inadequate.

What FDA found

  1. The firm did not test semen from directed donors for HIV-1, hepatitis C virus, hepatitis B virus by nucleic acid test, hepatitis B core antibody, or West Nile virus before determining the donors eligible.

    21 CFR 1271.85(a)
  2. The firm did not test semen from a directed donor for human T-lymphotropic virus types 1 and 2 (HTLV-I/II).

    21 CFR 1271.85(b)(1)
  3. The donor medical history questionnaire lacked required questions, timeframes, and deferral periods for communicable disease risk, including West Nile virus, variant Creutzfeldt-Jakob disease, and certain European military-base residence.

    21 CFR 1271.75(a)(1)
  4. The firm's procedures did not cover all steps and risk factors for donor screening, donor physical examination, determining donor eligibility, and other donor-eligibility requirements.

    21 CFR 1271.45–1271.90; 21 CFR 1271.47(a)

What FDA wants

FDA tells the firm to respond in writing within 15 working days with specific corrective steps and documentation. It also says oocytes and semen from donors with incomplete eligibility must stay in quarantine unless FDA grants an exemption, while embryos may be released only if labeled under 21 CFR 1271.90(b)-(c).

Who should pay attention

  • fertility clinics using directed semen donors
  • reproductive tissue banks and IVF labs
  • recipients and clinicians relying on donor eligibility screening

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Central Coast Multispecialty Medical Group, Inc.

    FDA warns Central Coast Multispecialty Medical Group over incomplete donor screening and eligibility for reproductive tissue.

    High risk
  2. Conceive Fertility Center

    FDA says Conceive Fertility Center in Dallas used incomplete donor screening and testing for reproductive cells.

    High risk
  3. Green Valley Fertility Partners

    FDA cited Green Valley Fertility Partners for donor eligibility failures involving oocyte HCT/Ps, including missing communicable disease testing and screening.

    High risk
  4. Lux Therapeutics LLC dba Ponya Therapeutics LLC

    FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.

    High risk